Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout

Comments
Loading...
  • Takeda Pharmaceutical Company Limited TAK announced the exercise of its option to acquire GammaDelta Therapeutics Limited, a T cell startup.
  • A little more than four years ago, Takeda stepped in to help bankroll GammaDelta Therapeutics with a $100 million injection.
  • Takeda will obtain GammaDelta's allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, including both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs.
  • Financial terms were not available.
  • The acquisition follows a multi-year collaboration between Takeda and GammaDelta formed in 2017 to develop GammaDelta's novel γδ T cell therapy platforms.
  • Takeda received an equity stake and an exclusive right to purchase GammaDelta. 
  • The deal is expected to be finalized in Q1 of Takeda's fiscal year 2022.
  • Price Action: TAK shares are down 0.11% at $13.84 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!